Compounds > estradiol-3-o-sulfamate
Page last updated: 2024-11-11

estradiol-3-o-sulfamate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6918339
CHEMBL ID219321
SCHEMBL ID628174
MeSH IDM0560906

Synonyms (32)

Synonym
e2mate
estradiol-3-o-sulfamate
j-995
bdbm50200937
estradiol 3-o-sulfamate
CHEMBL219321 ,
[(8r,9s,13s,14s,17s)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] sulfamate
SCHEMBL628174
YXYXCSOJKUAPJI-ZBRFXRBCSA-N
17beta-hydroxyestra-1,3,5(10)-trien-3-yl sulfamate
estradiol sulfamate
estra-1,3,5(10)-triene-3,17-diol (17beta)-, 3-sulfamate
unii-wo55odw08z
estradiol 3-sulfamate
HY-U00112
CS-7149
zk190628
ble-00084
zk-190628
estra-1,3,5(10)-triene-3,17-diol (17.beta.)-, 3-sulfamate
pgl2001
WO55ODW08Z ,
j995
pgl-2001
j995e
DB06597
172377-52-5
es-j 995
ble 00084
MS-25445
DTXSID801337121
AKOS040733128
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Steryl-sulfataseHomo sapiens (human)IC50 (µMol)0.01600.00010.40717.6000AID275881
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
steroid catabolic processSteryl-sulfataseHomo sapiens (human)
female pregnancySteryl-sulfataseHomo sapiens (human)
epidermis developmentSteryl-sulfataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
steryl-sulfatase activitySteryl-sulfataseHomo sapiens (human)
sulfuric ester hydrolase activitySteryl-sulfataseHomo sapiens (human)
metal ion bindingSteryl-sulfataseHomo sapiens (human)
arylsulfatase activitySteryl-sulfataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
lysosomeSteryl-sulfataseHomo sapiens (human)
endosomeSteryl-sulfataseHomo sapiens (human)
endoplasmic reticulumSteryl-sulfataseHomo sapiens (human)
endoplasmic reticulum lumenSteryl-sulfataseHomo sapiens (human)
endoplasmic reticulum membraneSteryl-sulfataseHomo sapiens (human)
Golgi apparatusSteryl-sulfataseHomo sapiens (human)
plasma membraneSteryl-sulfataseHomo sapiens (human)
membraneSteryl-sulfataseHomo sapiens (human)
intracellular membrane-bounded organelleSteryl-sulfataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID247396Inhibition of the growth of human breast cancer MCF-7 cells done for 2 hr at 37 degree C with compound2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
AID247400Concentration required to inhibit the growth of HCT116 human colon cancer cells by 50%2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
AID1249497Invivo inhibition of steroid sulfatase activity in healthy premenopausal women measured after 4 weeks2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.
AID247406Concentration required to inhibit the growth of OVCAR-3 human ovarian cancer cells by 50%2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
AID247390Concentration required to inhibit the growth of SF-539 human CNS cancer cells by 50%2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
AID275881Inhibition of STS in placental microsomes by radiometric assay2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity.
AID244799Mean graph midpoint (MGM) against a panel of human tumor cell lines2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
AID247387Concentration required to inhibit the growth of UACC-62 human melanoma cells by 50%2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
AID247409Concentration required to inhibit the growth of MDA-MB-435 human breast cancer cells by 50%2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
AID247405Concentration required to inhibit the growth of DU-145 human prostate cancer cells by 50%2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
AID1249492Inhibition of STS activity in human placental microsome2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.
AID1249498Invivo inhibition of steroid sulfatase activity in healthy premenopausal women measured after 4 weeks in presence estrogen production inhibitor NETA2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.
AID247389Concentration required to inhibit the growth of HOP-6 human lung cancer cells by 50%2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
AID247398Concentration required to inhibit the growth of SN12C human renal cancer cells by 50%2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's5 (71.43)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.63 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (14.29%)5.53%
Reviews2 (28.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (57.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
anastrozole
[no description available]		2.1110nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
letrozole
[no description available]		2.1110nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
norethindrone acetate
norethisterone acetate : A 3-oxo Delta(4)-steroid that is norethisterone in which the hydroxy group has been converted to its acetate ester.		3.48113-oxo-Delta(4) steroid;
acetate ester;
terminal acetylenic compound		progestin;
synthetic oral contraceptive
estrone
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.		3.211017-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
norethindrone
Norethindrone: A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION.. norethisterone : A 17beta-hydroxy steroid that is testosterone in which the hydrogen at position 17 is replaced by an ethynyl group and in which the methyl group attached to position 10 is replaced by hydrogen.		3.481117beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol		progestin;
synthetic oral contraceptive
2-methoxyestradiol
2-methoxy-17beta-estradiol : A 17beta-hydroxy steroid, being 17beta-estradiol methoxylated at C-2.		2.462017beta-hydroxy steroid;
3-hydroxy steroid		angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite
estrone-3-o-sulfamate
estrone-3-O-sulfamate: a steroid sulfatase inhibitor		4.0740
ym 511
YM 511: a non-steroidal aromatase inhibitor; structure given in first source		2.1110
2-methoxyestrone
2-methoxyestrone : A 17-oxo steroid that is estrone in which the hydrogen at position 2 has been replaced by a methoxy group.		2.021017-oxo steroid;
3-hydroxy steroid;
alicyclic ketone;
aromatic ether;
phenolic steroid;
phenols		human metabolite;
mouse metabolite
irosustat
irosustat: Antineoplastic Agents, Hormonal; a tricyclic sulfamate ester; structure in first source		3.1810
vorozole
vorozole: structure given in first source; vorozole/R 83842 is ((+)/dextro-isomer), RN 129731-10-8; R 83839 ((-)/levo-isomer)		2.1110benzotriazoles
2-methoxyestradiol-3,17-o,o-bis(sulfamate)
2-methoxyestradiol-3,17-O,O-bis(sulfamate): an antiangiogenic microtubule disruptor; antineoplastic agent; structure in first source		2.4620
2-meoemate
[no description available]		2.4620
4-methylcoumarin 7-o-sulfamate
[no description available]		2.1110
2-ethylestradiol sulfamate
2-ethyloestradiol-bis-sulfamate: structure in first source		2.4620
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		3.2110benzenes;
hydroxycoumarin;
methyl ketone
ConditionIndicatedRelationship StrengthStudiesTrials
Carcinoma, Lewis Lung
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.		02.0310
Breast Cancer
[description not available]		03.6730
Angiogenesis, Pathologic
[description not available]		02.0310
Breast Neoplasms
Tumors or cancer of the human BREAST.		03.6730
Endometrioma
An enlarged area of ENDOMETRIOSIS that resembles a tumor. It is usually found in the OVARY. When it is filled with old blood, it is known as a chocolate cyst.		03.6930
Cancer of Prostate
[description not available]		03.4220
Endometriosis
A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum.		03.6930
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		03.4220
Acetyl-CoA:alpha-Glucosaminide N-Acetyltransferase Deficiency
[description not available]		0310
Mucopolysaccharidosis III
Mucopolysaccharidosis characterized by heparitin sulfate in the urine, progressive mental retardation, mild dwarfism, and other skeletal disorders. There are four clinically indistinguishable but biochemically distinct forms, each due to a deficiency of a different enzyme.		0310